Merger Investigations - Penumbra, Inc. is set to be acquired by Boston Scientific Corporation in a cash and stock transaction valuing Penumbra at $374 per share, with an enterprise value of approximately $14.5 billion. The investigation focuses on whether the Penumbra Board breached its fiduciary duties by failing to conduct a fair process and whether the deal provides fair value to shareholders [2] - Calavo Growers, Inc. will be acquired by Mission Produce, Inc., with Calavo stockholders receiving $27.00 per share, consisting of $14.85 in cash and 0.9790 shares of Mission for each share of Calavo. The total enterprise value of the transaction is approximately $430 million. The investigation examines if the Calavo Board breached its fiduciary duties regarding the fairness of the deal [4] - Clearwater Analytics Holdings, Inc. is being acquired by a Permira and Warburg Pincus-led Investor Group for $24.55 per share in cash, amounting to approximately $8.4 billion. The investigation looks into whether the Clearwater Analytics Board failed to conduct a fair process and if the deal consideration is fair for shareholders [6]

Core Viewpoint - Ademi LLP is investigating Penumbra for potential breaches of fiduciary duty and other legal violations related to its transaction with Boston Scientific [1] Group 1: Transaction Details - Penumbra stockholders can choose to receive either $374 in cash or 3.8721 shares of Boston Scientific common stock per share, with the total transaction consideration being approximately 73% in cash and 27% in stock [2] - Penumbra insiders are set to receive significant benefits as part of the change of control arrangements [2] Group 2: Board Conduct and Limitations - The transaction agreement imposes significant penalties on Penumbra for accepting competing bids, which may limit the board's ability to consider other offers [3] - The investigation focuses on whether the Penumbra board is fulfilling its fiduciary duties to all shareholders amid these limitations [3]

医疗科技公司Penumbra(PEN.US)大涨超12%，最高触及351.67美元，创历史新高。消息面上，波士顿科 学将以现金加股票的方式收购Penumbra，每股对价为374美元，较Penumbra周三收盘价溢价约19%。该 交易的股权价值约为145亿美元，预计将在今年内完成。(格隆汇) ...

Core Viewpoint - Boston Scientific plans to acquire Penumbra for $14.5 billion, leading to an 11.5% surge in Penumbra's stock price while Boston Scientific's stock price fell by 5.5% [1] Company Summary - Boston Scientific is making a significant move by proposing a $14.5 billion acquisition of Penumbra [1] - Following the announcement, Penumbra's stock experienced an increase of 11.5% [1] - In contrast, Boston Scientific's stock saw a decline of 5.5% after the acquisition news [1]

Group 1 - TSMC's stock rose by 5.2%, reaching an all-time high, with Q4 performance and 2026 outlook exceeding expectations [1] - ASML's stock increased by 7.2%, also hitting a historical peak, driven by TSMC's strong performance and bullish outlook from Morgan Stanley [1] - Spotify's stock saw a 2.0% rise after announcing a price increase for subscriptions in the US and other regions [1] Group 2 - Boston Scientific's stock fell by 6.2% following the announcement of its acquisition of Penumbra for $14.5 billion [1] - Penumbra's stock surged by 11.7% in response to the acquisition news [1]

Group 1 - Boston Scientific (BSX.US) has agreed to acquire medical device manufacturer Penumbra (PEN.US) for a valuation exceeding $14 billion [1] - Penumbra's stock price rose over 12% in pre-market trading, reaching $352.6 [1] - The acquisition will be executed through a combination of cash and stock, with a per-share price of $374, representing a premium of approximately 19% over Penumbra's closing price on Wednesday [1] Group 2 - Penumbra shareholders can choose to receive $374 in cash per share or exchange for 3.8721 shares of Boston Scientific common stock [1] - The equity value of the transaction is approximately $14.6 billion, and it is expected to be completed within this year [1]

Core Viewpoint - Boston Scientific (BSX.US) has agreed to acquire medical device manufacturer Penumbra (PEN.US) for a valuation exceeding $14 billion, with Penumbra's stock price rising over 12% in pre-market trading to $352.6 [1] Group 1: Acquisition Details - The acquisition will be executed through a combination of cash and stock, with a per-share price of $374, representing a premium of approximately 19% over Penumbra's closing price on Wednesday [1] - Penumbra shareholders have the option to receive either $374 in cash per share or convert their shares into 3.8721 shares of Boston Scientific common stock [1] - The equity value of the transaction is approximately $14.6 billion, and it is expected to be completed within this year [1]

Core Viewpoint - Boston Scientific plans to acquire Penumbra for approximately $14.5 billion, enhancing its cardiovascular and vascular intervention portfolio to meet the growing demand for minimally invasive treatments for blood clots and strokes [1][2]. Financial Details - The acquisition values Penumbra at $374 per share, a 19% premium over its closing price of $313.43 [2]. - The deal has an enterprise value of about $14.5 billion, excluding Penumbra's net cash and short-term investments of approximately $470 million [2]. - Boston Scientific intends to finance the $11 billion cash portion through a combination of cash on hand and new debt [3]. - The transaction is expected to be dilutive to adjusted earnings per share by $0.06 to $0.08 in the first year post-closing, neutral to slightly accretive in the second year, and increasingly accretive thereafter [3]. Strategic Rationale - The acquisition allows Boston Scientific to enter fast-growing segments within the vascular space, leveraging Penumbra's mechanical thrombectomy devices designed for blood clot removal [4]. - Penumbra's technologies are expected to complement Boston Scientific's existing offerings and expand access to advanced treatments globally [6]. Market Context - Cardiovascular diseases are the leading cause of death worldwide, driving demand for advanced treatment tools for conditions like pulmonary embolism and stroke [5]. - Penumbra anticipates fourth-quarter revenue growth of approximately 21.4% to 22.0%, with full-year 2025 revenue projected at around $1.4 billion, reflecting a growth of about 17.3% to 17.5% from the previous fiscal year [8][9]. Broader Acquisition Strategy - This announcement follows Boston Scientific's recent agreement to acquire Valencia Technologies Corporation, indicating a strategy to broaden its technology base across cardiovascular, neurovascular, and urology markets [10][11].

Boston Scientific has agreed to acquire Penumbra in a cash-and-stock deal worth $14.5 billion. ...

Core Viewpoint - Penumbra's stock experienced a significant increase of approximately 14% following the announcement of a deal on Thursday morning [1] Group 1 - The announcement of the deal positively impacted Penumbra's stock performance, indicating strong market reaction [1]